200 related articles for article (PubMed ID: 9373338)
1. An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL-2R.
Harvill ET; Morrison SL
Immunotechnology; 1995 Aug; 1(2):95-105. PubMed ID: 9373338
[TBL] [Abstract][Full Text] [Related]
2. An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: real time measurement of ligand binding.
Harvill ET; Morrison SL
Mol Immunol; 1996 Aug; 33(11-12):1007-14. PubMed ID: 8960125
[TBL] [Abstract][Full Text] [Related]
3. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
4. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
5. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
6. Effects of interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors.
Jadus MR; Good RW; Crumpacker DB; Yannelli JR
J Leukoc Biol; 1991 Feb; 49(2):139-51. PubMed ID: 1991997
[TBL] [Abstract][Full Text] [Related]
7. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.
Hadley AG; Zupanska B; Kumpel BM; Leader KA
Immunology; 1992 Jul; 76(3):446-51. PubMed ID: 1356095
[TBL] [Abstract][Full Text] [Related]
8. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice.
Kunzendorf U; Pohl T; Bulfone-Paus S; Krause H; Notter M; Onu A; Walz G; Diamantstein T
J Clin Invest; 1996 Mar; 97(5):1204-10. PubMed ID: 8636431
[TBL] [Abstract][Full Text] [Related]
9. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo suppression of interleukin-2-activated killer cell activity by chimeric proteins between interleukin-2 and Pseudomonas exotoxin.
Puri RK; FitzGerald D; Leland P; Kozak RW; Pastan I
Cell Immunol; 1992 Sep; 143(2):324-34. PubMed ID: 1511480
[TBL] [Abstract][Full Text] [Related]
11. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor.
Heaton KM; Ju G; Morris DK; Delisio K; Bailon P; Grimm EA
Cell Immunol; 1993 Mar; 147(1):167-79. PubMed ID: 8462109
[TBL] [Abstract][Full Text] [Related]
12. Phorbol myristate acetate-induced expression of high-affinity interleukin 2 receptors and production of interleukin 2 by human acute lymphoblastic leukemia T cells.
Sahraoui Y; Allouche M; Perrakis M; Clemenceau C; Jasmin C; Georgoulias V
Leukemia; 1992 Apr; 6(4):295-303. PubMed ID: 1588792
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors.
Blay JY; Bertoglio J; Fradelizi D; Chouaib S
Int J Cancer; 1989 Oct; 44(4):598-604. PubMed ID: 2793231
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Tsang KY; Finch MD; Primus FJ; Schlom J
Cancer Immunol Immunother; 1991; 34(1):9-16. PubMed ID: 1836975
[TBL] [Abstract][Full Text] [Related]
15. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
Bamford RN; Grant AJ; Burton JD; Peters C; Kurys G; Goldman CK; Brennan J; Roessler E; Waldmann TA
Proc Natl Acad Sci U S A; 1994 May; 91(11):4940-4. PubMed ID: 8197161
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor (IL-2R) by a novel cytokine interleukin-1 receptor antagonist (IL-1ra).
Conti P; Panara MR; Porrini AM; Gambi D; Barbacane RC; Reale M; Bongrazio M; Dempsey RA
Scand J Immunol; 1992 Jul; 36(1):27-33. PubMed ID: 1535451
[TBL] [Abstract][Full Text] [Related]
17. An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression.
Bulfone-Paus S; Rückert R; Krause H; von Bernuth H; Notter M; Pohl T; Tran TH; Paus R; Kunzendorf U
Transplantation; 2000 Apr; 69(7):1386-91. PubMed ID: 10798759
[TBL] [Abstract][Full Text] [Related]
18. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
Ortaldo JR; Frey J; Takeshita T; Sugamura K
Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
[TBL] [Abstract][Full Text] [Related]
19. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
20. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
